Nurix Therapeutics, Inc. Q1 Loss increases, but beats estimates

Nurix Therapeutics, Inc. (NRIX) announced Loss for its first quarter that increased from last year but beat the Street estimates.

The company's bottom line came in at -$41.518 million, or -$0.76 per share. This compares with -$40.733 million, or -$0.75 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$0.8 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 30.7% to $16.585 million from $12.685 million last year.

Nurix Therapeutics, Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$41.518 Mln. vs. -$40.733 Mln. last year.
-EPS (Q1): -$0.76 vs. -$0.75 last year.
-Revenue (Q1): $16.585 Mln vs. $12.685 Mln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com